1. Accelerating Approval and Reducing Costs of Spray Dried Drugs through Development by Design (DbD)

    Filipe Gaspar, Vice President, R&D and Márcio Temtem, Ph.D., Associate Director for Particle Design & Formulation at Hovione explain Development by Design (DbD).

  2. Achieving a High Level of Customer Service Through Lean Quality Management

    Warren Horton, Executive Vice President Global Quality Assurance and Regulatory at Avara Pharmaceutical Services discusses the real foundation of customer service.

  3. Differentiating Generic SODFs with Hard Capsule Formulations

    With lower development costs and greater flexibility, hard capsules are the best choice for the formulation of generic solid oral dosage pharmaceuticals, explains Jonathan Gilinski, Executive Director for CapsCanada.

  4. Innovating Equipment: Inline Buffer Dilution Technology

    Nice Insight is in conversation with Kimo Sanderson, at Asahi Kasei Bioprocess America, to discuss the company’s “technology of the decade.”

  5. Implications of Serialization for the U.S. Pharma Industry
    Lee Murtagh and Walter Hoberg III of Alcami explain the upcoming regulatory impact on the industry.
  6. Perspectives on Product Pricing Strategy and Practice
    Getting pricing “right” is a tricky balancing act, but one that offers tremendous value for all.
  7. Elysium Health™ Announces Exclusive License for Use of Nicotinamide Riboside for the Slowing of Aging and Prevention of Age-Related Diseases from Mayo Clinic and Harvard

    Aging is the single greatest risk factor for major debilitating and life-threatening conditions, including cancer, cardiovascular disease, and neurodegeneration.

  8. Patients with Rare Leukemia Disease Will Have New Treatment Option

    US FDA approves AstraZeneca’s Lumoxiti (moxetumomab pasudotox) for the treatment of patients with hairy cell leukemia (HCL) who have undergone at least two prior therapies.


  9. New Genetic Understanding Could Lead to Brain Cancer Treatments

    Researchers have identified the gene mutation that leads to the brain cancer glioblastoma


  10. Xeris Pharmaceuticals and OHSU Conducting Artificial Pancreas Clinical Trial Using Xeris’ Novel Ready-to-Use Liquid Glucagon

    Patients enrolling in Phase 1 clinical trial using Xeris’ ready-to-use liquid glucagon formulation as part of a fully integrated, dual-hormone closed-loop system.

  11. Meeting the Changing Demands for Sterile-Fill Finish Operations

    Justin Kadis, Business Development for Federal Equipment Company, discusses optimized and error-free fill-finish operations.

  12. Supporting Patient-Centric Clinical Trials from Point-of-Origin through the Last Mile

    Wes Wheeler, CEO of Marken explains how Direct-to-Patient (DTP) clinical trials are becoming an industry standard.

  13. Uniting the Industry for the Prevention of “Pharmageddon”
    Tim Tyson Chairman and CEO of Avara Pharmaceutical Services explains Pharmageddon and how to prevent it.
  14. With Respect to Supplier-Partner Relationships, What is Your Preferred Collaboration Model?
    Experts weigh in on our Roundtable question. 
  15. Reducing Time to Market with Targeted Regulatory Affairs Support

    Regulatory affairs activities are essential components of any drug development and commercialization program, explains Maryse Phan, Head of Regulatory Affairs for API Manufacturing, Servier.

  16. Speeding Development and Reducing Costs with Analytical Quality by Design

    António Ramos, Analytical Chemistry Group Leader, Process Chemistry Development and Rui Loureiro, Director of the R&D Process Chemistry at Hovione outline Quality by Design (QbD) in analytical method development.

  17. Allergan Makes Neurotoxin Buy with Acquisition of Bonti Inc.

    Purchase gives Allergan entry into the market for neurotoxin with cosmetic and medical uses.

  18. J&J Anticipates Growth

    Launches and label extensions are anticipated to drive profits.

  19. Biohaven Reports Positive Results From Double-Blind, Placebo-Controlled, Investigator Initiated, Proof Of Concept Trial Of BHV-0223 For Anxiety

    The company announced positive results from the trial, evaluating the effect of BHV-0223 in patients diagnosed with social anxiety disorder and public speaking anxiety while performing an anxiety-provoking speech task.

  20. Regeneron and Teva Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip

    Fasinumab-treated patients experienced significantly less pain and significantly improved functional ability from baseline compared to placebo.

Nice Insight Awareness/Perception Scorecard

Research. Compare. Contact. Find the Ideal Partner.

Customer Awareness (CA) describes a buyer’s knowledge of your offering, while Customer Perception (CP) describes how a buyer rates your company based on that knowledge. Nice Insight’s CA/CP scorecard allows you to measure market awareness and perception of you and your industry peers based on acknowledged outsourcing drivers.

  1. Search by company type, region, market segment and services.
  2. Select up to 5 companies to compare.
  3. View CA & CP performance scores against industry benchmark ratings.

New Genetic Understanding Could Lead to Brain Cancer Treatments

Sep 21, 2018 10:59:39 AM PAO-M09-18-NI-017
Drug Development

Patients with Rare Leukemia Disease Will Have New Treatment Option

Sep 21, 2018 10:57:13 AM PAO-M09-18-NI-016

Allergan Makes Neurotoxin Buy with Acquisition of Bonti Inc.

Sep 19, 2018 4:15:43 PM PAO-M09-18-NI-015

J&J Anticipates Growth

Sep 19, 2018 4:07:28 PM PAO-M09-18-NI-014
  • CDMO
  • Pharma

Preparing for Hurricane Florence in Pharma

Sep 18, 2018 3:11:56 PM PAO-M09-18-NI-013
FDA Approval

Latest Apple Watch Gets FDA Approval as a Class II Device

Sep 18, 2018 2:54:20 PM PAO-M09-18-NI-012

Transforming with an Equipment Partner: Preparing the Industry for Serialization

Sep 17, 2018 6:00:00 AM PAO-M09-18-CL-001

Novartis Unloads Sandoz US Components

Sep 14, 2018 1:17:21 PM PAO-M09-18-NI-011

Ophthalmic Drug Developer Kodiak BioSciences Files for IPO

Sep 14, 2018 1:15:11 PM PAO-M09-18-NI-010

EU Gives Nod to KEYTRUDA and Chemotherapy Combination Treatment

Sep 14, 2018 1:12:10 PM PAO-M09-18-NI-009
Breakthrough Therapy

Breakthrough Therapy Designation for New Asthma Drug

Sep 13, 2018 2:38:31 PM PAO-M09-18-NI-008
Drug Development

Sanofi-Aventis Collaborates with Dyadic International on Cl Gene Expression

Sep 13, 2018 2:34:36 PM PAO-M09-18-NI-007

Nice Insight Overview

Changes in the  Biopharma Industry: from Minor to Major Evolution
New technologies such as gene editing are leading to the development of even more advanced, targeted medicines.

The Next-Generation Player

Addressing Development Challenges for Complex Biologic Drug Candidates
At Lonza, we are constantly looking to reduce the development timeline, giving our customers more control over their projects.

Karen Fallen, Vice President, Business Unit Head of Clinical Development & Manufacturing Lonza Pharma & Biotech

M+A Column

Inside Mergers & Acquisitions
Kevin Bottomley Partner, Results Healthcare
Deals in the pharmaceutical industry are an important mechanism of acquiring innovation, business and efficiency.

Nice Insight Overview

Doping: Famous Cases, Substances and Values in Sports

Marc Technow, Nice Insight